Additionally, the use of RNA interference technology to knock down ABCG2 expression has yielded promising results in preclinical models, further supporting the therapeutic potential of targeting ABCG2 in glioma treatment [48]. The gene discussed is ABCG2; the disease is central nervous system cancer.